CLIA (Veridien Climate Action ETF) is no longer actively trading.
This usually means the fund has been liquidated, merged into another product, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.

The fund seeks to achieve its investment objective by investing in equity securities (or corresponding American Depositary Receipts (“ADRs”)) of U.S. and foreign companies, whose activities, business models, or products make a substantial contribution to mitigating climate change. The fund invests in ADRs to gain exposure to foreign companies, which may include those based in both developed and emerging markets.
Is CLIA's expense ratio expensive, average, or a steal for its category?
Pro reveals the verdict on a 5-tier spectrum calibrated against ICI 2025 industry averages, with strategy-aware bands so the comparison is meaningful.

CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics launched its in-house, high-complexity CLIA-certified laboratory in Iowa City, Iowa.

Allarity Therapeutics is now poised to run its DRP ® testing in-house in a CLIA-certified laboratory environment The FDA requires that biomarker testing to select patients for registration trials must be performed in a CLIA-certified laboratory environment CLIA certification for the Allarity Therapeutics Medical Laboratory is a critical strategic initiative to streamline the development of Allarity's lead agent, stenoparib Positions Allarity Therapeutics Medical Laboratory as a preferred CLIA-certified partner for European companies pursuing U.S. clinical trials or commercialization TARPON SPRINGS, Fla., July 7, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor—today announced that it has obtained a Certificate of Registration under the Clinical Laboratory Improvement Amendments (CLIA) for its in-house laboratory.

[url="]bioAffinity Technologies, Inc.[/url] (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detectio

GRAIL Presents PATHFINDER 2 Results of More Than 35,000 Participants Showing the Galleri Test Substantially Increased Cancer Detection With R

GRAIL Reports Full Results From NHS-Galleri Trial Demonstrating Substantial Reduction in Stage IV Cancer Diagnoses at 2026 ASCO Annual Meeting